Unknown

Dataset Information

0

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.


ABSTRACT: Bispecific antibodies enable unique therapeutic approaches but it remains a challenge to produce them at the industrial scale, and the modifications introduced to achieve bispecificity often have an impact on stability and risk of immunogenicity. Here we describe a fully human bispecific IgG devoid of any modification, which can be produced at the industrial scale, using a platform process. This format, referred to as a ??-body, is assembled by co-expressing one heavy chain and two different light chains, one ? and one ?. Using ten different targets, we demonstrate that light chains can play a dominant role in mediating specificity and high affinity. The ??-bodies support multiple modes of action, and their stability and pharmacokinetic properties are indistinguishable from therapeutic antibodies. Thus, the ??-body represents a unique, fully human format that exploits light-chain variable domains for antigen binding and light-chain constant domains for robust downstream processing, to realize the potential of bispecific antibodies.

SUBMITTER: Fischer N 

PROVIDER: S-EPMC4339886 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.

Fischer Nicolas N   Elson Greg G   Magistrelli Giovanni G   Dheilly Elie E   Fouque Nicolas N   Laurendon Amélie A   Gueneau Franck F   Ravn Ulla U   Depoisier Jean-François JF   Moine Valery V   Raimondi Sylvain S   Malinge Pauline P   Di Grazia Laura L   Rousseau François F   Poitevin Yves Y   Calloud Sébastien S   Cayatte Pierre-Alexis PA   Alcoz Mathias M   Pontini Guillemette G   Fagète Séverine S   Broyer Lucile L   Corbier Marie M   Schrag Delphine D   Didelot Gérard G   Bosson Nicolas N   Costes Nessie N   Cons Laura L   Buatois Vanessa V   Johnson Zoe Z   Ferlin Walter W   Masternak Krzysztof K   Kosco-Vilbois Marie M  

Nature communications 20150212


Bispecific antibodies enable unique therapeutic approaches but it remains a challenge to produce them at the industrial scale, and the modifications introduced to achieve bispecificity often have an impact on stability and risk of immunogenicity. Here we describe a fully human bispecific IgG devoid of any modification, which can be produced at the industrial scale, using a platform process. This format, referred to as a κλ-body, is assembled by co-expressing one heavy chain and two different lig  ...[more]

Similar Datasets

| S-EPMC5297495 | biostudies-literature
| S-EPMC2840394 | biostudies-literature
| S-EPMC7709125 | biostudies-literature
| S-EPMC5567192 | biostudies-other
| S-EPMC7392990 | biostudies-literature
| S-EPMC6748609 | biostudies-literature
| S-EPMC4661895 | biostudies-literature
| S-EPMC5606552 | biostudies-literature
| S-EPMC2841541 | biostudies-literature
2023-06-01 | GSE176119 | GEO